Partner with Top Asian Biopharma Executives at BIO Asia

On April 8-9, 2014, a diverse group of innovative companies and Japanese dealmakers will come together in a collaborative setting for partnering meetings, company presentations, networking and targeted programming at the 11th annual BIO Asia International Conference.

Japan’s presence as the 2nd largest pharmaceutical industry in the world, bolstered by an evolving Asia-Pacific partnering landscape, means biopharma companies cannot ignore the deal opportunities that are being created in this dynamic market.

Industry leaders have recognized Japan as being ripe with partnership opportunities for biopharma companies this year. Joseph Panetta, president and CEO of Biocom, told Genetic Engineering & Biotechnology News (GEN), “Japan’s moves toward building biopharma appear to give U.S. companies a faster option for expansion into Asia than has been seen after a decade of engagement with China.” Similarly, JP Morgan healthcare specialist Scott Braunstein has touted the direct access that the Japanese pharma landscape has afforded Western companies, saying, “’Many pharma companies have a free run into Japanese markets as it has become so open.”

This kind of participation demonstrates why two days spent at BIO Asia will help your company build the important relationships that are required to succeed in the Asian partnering environment. BIO’s One-on-One Partnering™ system makes this possible by enabling senior executives to arrange private meetings to explore licensing and research collaborations.

BIO Asia also provides a platform for emerging and established innovative Western and Asian biopharma companies to reach new potential partners and tell their story. If you are interested in applying for a company presentation slot, we encourage you to submit your application today. Less than 5 spots remain. See the list of currently confirmed 2014 presenting companies here.

There’s no better time to strengthen your ties with the Japanese biotechnology sector. Additional details about this year’s program, BIO One-on-One Partnering™ and presentation opportunities, as well as registration information, can be found at We look forward to welcoming you to Tokyo!

Find Your Next Asia Partnership in Tokyo at BIO Asia

On April 8-9, 2014, the BIO Asia International Conference will enter its eleventh year. This year, biopharma industry leaders will convene at the Grand Hyatt in Tokyo, Japan to make the cross border deals that will advance collaboration between Asia and the West. This event has become the premier customized partnering event for Western and Asian biopharma executives. According to JP Morgan healthcare specialist Scott Braunstein, Japan has become one of the most critical markets for pharma and biotech firms. Japan currently holds the spot for the second largest pharmaceutical market in the world.

Asian biopharmas at this year’s plenary sessions will include Acucela Inc., TaiGen Biotechnology Co., Ltd., Pfizer (Asia), Baxter (Japan), and Taiwan Liposome Company, Ltd. The speakers and the full descriptions for the 2014 panels can be viewed here. In addition, the following list of Asian biopharma companies will be available for One-on-One Partnering, with more being added daily:

Acucela, Inc.
Allergan Singapore Pte Ltd.
Asahi Kasei Corporation
ASLAN Pharmaceuticals Pte Ltd.
Astellas Pharma, Inc.Baxter
Beijing Fogangren Bio-Pharm Tech, Co., Ltd.
Chugai Pharmaceutical Co., Ltd.
Curadev Pharma Pvt Ltd.
Daiichi Sankyo, Inc.
Dong-A ST
Dr.Reddy’s Laboratories Ltd.
Fresenius Kabi Asia Pacific Ltd.
Generon (Shanghai) Corporation
Global Health Innovative Technology Fund (GHIT Fund)
Golden Biotechnology Corporation
Hisamitsu Pharma
Hua Medicine
ICS Convention Design, Inc.
Ildong Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.
Jeil Pharmaceutical
JCR Pharma
JT Pharma
Kissei Pharmaceutical Co., Ltd.
Lilly China Research and Development Co., Ltd.
Lundbeck Research China
Mitsubishi Tanabe Pharma Corporation
Mitsui Chemicals Inc.
Nippon Kayaku Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Pluristem Therapeutics, Inc.
ReqMed Company, Ltd.
Sosei Co. Ltd.
TaiGen Biotechnology Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
Taiwan Liposome Company Co., Ltd. (TLC)
Takeda Pharmaceutical Co., Ltd.
Tanaka International, LLC
Tech Manage Corp.
Teva Pharmaceutical Industries Ltd.
Tokyo Stock Exchange, Inc.

There is growing interest in U.S. partnerships by Japanese biopharmas, as evident in several recent deals including Ajinomoto’s $175 million acquisition of San Diego-based Althea Technologies last year. One reason why Japan has become popular among Western biotech and pharma companies is the direct access available in Japan to end markets. Leading biotech companies such as Celgene can sell their products straight into the Japanese market and enjoy overwhelming success.

Registration for the BIO Asia International Conference is open, and BIO’s One-on-One PartneringTM System has launched. Don’t miss this chance to capitalize on the growing opportunities for collaboration available in Asia- register today!